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Abstract
 
Osteoclasts are multinucleated cells that resorb bones, and are derived from hematopoietic cells
of the monocyte/macrophage lineage. The receptor activator of NF-
 
 
 
B ligand (RANKL, also
called ODF/TRANCE/OPGL) stimulates both osteoclast differentiation from osteoclast pro-
genitors and activation of mature osteoclasts. To identify genes responsible for osteoclast differ-
entiation, we used a molecular indexing technique. Here, we report a clone of one of these
genes whose transcription is induced by soluble RANKL (sRANKL) in both the RAW264.7
cells of the mouse macrophage cell line and the mouse primary bone marrow cells. The pre-
dicted protein was found to be a mouse homologue of Jun dimerization protein 2 (JDP2), a
member of the AP-1 family of transcription factors, containing a basic region-leucine zipper
motif. Transient transfection experiments revealed that overexpression of JDP2 leads to activa-
tion of both tartrate-resistant acid phosphatase (TRAP) and cathepsin K gene promoters in
RAW264.7 cells. Infection of mouse primary bone marrow cells with retroviruses expressing
JDP2-facilitated sRANKL-mediated formation of TRAP-positive multinuclear osteoclasts.
Importantly, antisense oligonucleotide to JDP2 strongly suppressed sRANKL-induced osteo-
clast formation of RAW264.7 cells. Our findings suggest that JDP2 may play an important role
in the RANK-mediated signal transduction system, especially in osteoclast differentiation.
Key words: bone resorption • signal transduction • osteoclastogenesis • molecular indexing • 
mitogen-activated protein kinase
 
Introduction
 
Osteoclasts are multinucleated cells derived from hemato-
poietic progenitors of the monocyte/macrophage lineage.
The receptor activator of NF-
 
 
 
B (RANK)
 
*
 
 ligand
(RANKL; also known as ODF/TRANCE/OPGL) is a
newly discovered member of the TNF superfamily of cy-
tokines that stimulate osteoclast differentiation from osteo-
clast progenitor cells in the presence of macrophage col-
ony-stimulating factor (M-CSF; 1, 2). Bone marrow
stroma/osteoblasts produce RANKL on their cell surface in
response to several osteotropic factors, whereas osteoclast
progenitors express a receptor for RANKL, RANK, which
is a member of the TNF receptor superfamily (1, 3). Re-
cently, it was reported that mice lacking RANKL or
RANK also lack osteoclasts. These mice have profound
defects in bone resorption and exhibit an osteopetrotic
phenotype (4, 5). Transgenic mice that overexpress a solu-
ble RANK–Fc fusion protein have severe osteopetrosis be-
cause of a reduction in osteoclasts, which is similar to
OPG/osteoclastogenesis-inhibitory factor transgenic mice
(6). Therefore, the RANKL/RANK system is found to be
physiologically crucial for osteoclast formation. It is likely
that dysfunction or modulation of the RANKL/RANK
system is associated with diseases such as postmenopausal
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Abbreviations used in this paper:
 
 EGFP, enhanced green fluorescent pro-
tein; JDP2, Jun dimerization protein 2; JNK, c-Jun NH
 
2
 
-terminal kinase;
IRES, internal ribosome entry site; MAPK, mitogen-activated protein ki-
nase; M-CSF, macrophage colony-stimulating factor; RANK, receptor
activator of NF-
 
 
 
B; RANKL, RANK ligand; sRANKL, soluble
RANKL; TRAP, tartrate-resistant acid phosphatase. T
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osteoporosis (7–9), destruction of bone in rheumatoid ar-
thritis (10), and bone metastasis of cancer cells (11).
RANK, like other TNF receptor superfamily proteins, is
known to activate a cascade of intracellular signaling events,
including interactions with TNF receptor-associated factors
and activation of both c-Jun NH
 
2
 
-terminal kinase (JNK)
and NF-
 
 
 
B pathway (12, 13). So far, only a limited number
of intracellular signaling molecules, such as NF-
 
 
 
B (12),
c-Fos (14), and Fra-1 (15) have been shown to be involved
in osteoclast differentiation. Identification of other factors
that participate in osteoclast differentiation and their func-
tions are needed to elucidate the detailed molecular signal-
ing of RANK, which induces osteoclast differentiation.
Here, we describe the isolation and characterization of a
member of the AP-1 family of transcription factors, Jun
dimerization protein 2 (JDP2). We present evidence, based
on expression profiles and signaling capability to activate
osteoclast differentiation of mouse RAW264.7 and primary
bone marrow cells, that JDP2 may be a key regulator of os-
teoclast differentiation.
 
Materials and Methods
 
Preparation of a Soluble RANKL (sRANKL). 
 
Recombinant
sRANKL was expressed in 
 
Escherichia coli
 
 strain TOP10 (Invitro-
gen) as a fusion protein of an extracellular domain of mouse
RANKL (Gln
 
137
 
 to Asp
 
316
 
) and the COOH-terminal end of glu-
tathione 
 
S
 
-transferase, and purified by affinity chromatography
through a glutathione-Sepharose 4B gel, anion exchange chro-
matography, and gel filtration chromatography.
 
Cell Culture. 
 
RAW264.7 and J774A.1 cells were purchased
from Dainippon Pharmaceutical. The cells were maintained at
37
 
 
 
C in a humidified atmosphere of 5% CO
 
2
 
 in DMEM supple-
mented with 10% heat-inactivated (56
 
 
 
C for 30 min) FCS, 100
µg/ml streptomycin, and 100 U/ml penicillin (all from Life
Technologies). Mouse primary bone marrow cells were obtained
from femurs and tibias of 8-wk-old ddY mice.
 
Molecular Indexing (16). 
 
Two cDNA pools were synthesized
from total RNA (30 µg) isolated from untreated and sRANKL-
treated (100 ng/ml, 48 h) RAW264.7 cells, with SuperScript
II RNaseH
 
 
 
 reverse transcriptase (Life Technologies). The
primer for the first strand cDNA synthesis was a mixture of
the following three primers: 5
 
 
 
-GGATCCTTTTTTTTTTT-
TTTTTA-3
 
 
 
 (DAPA1), 5
 
 
 
-CAGCTGTTTTTTTTTTTTTT-
TTC-3
 
 
 
 (DAPC1), and 5
 
 
 
-CTCGAGTTTTTTTTTTTTTTTTG-
3
 
 
 
 (DAPG1). The two cDNA pools were digested with FokI
(Takara Bio Inc.) and ligated with either one of the following
adaptors: C1T adaptor, 5
 
 
 
-biotin-GTACATATTGTCGTTA-
GAACGCT-3
 
 
 
 (sense), 5
 
 
 
-NXYZAGCGTTCTAACGAC-
AATATGTAC-3
 
 
 
 (antisense); and C1G adaptor, 5
 
 
 
-bio-
tin-GTACATATTGTCGTTAGAACGCG-3
 
 
 
 (sense), 5
 
 
 
-
NXYZCGCGTTCTAACGACAATATGTAC-3
 
 
 
 (antisense).
The ligated products were recovered by Dynabeads M-280
streptavidin (Dynal) and reconstituted to 50 µl with 5 U of
Stoffel fragment (Applied Biosystems). Using TAMRA-labeled
C1S (5
 
 
 
-GTACATATTGTGTTAGAACGC-3
 
 
 
; Applied Bio-
systems) and one of the anchored oligo (dT) primers (DAPA1,
DAPC1, or DAPG1), PCR was performed under the following
conditions: predenaturation at 94
 
 
 
C for 2 min, 35 cycles of
DNA amplification (at 94
 
 
 
C for 30 s, 55
 
 
 
C for 1 min, and 72
 
 
 
C
for 1 min), and final elongation at 72
 
 
 
C for 10 min. Supernatant
was loaded on a denaturing polyacrylamide gel, and the bands
were analyzed by Molecular Imager Fx (Bio-Rad Laboratories).
Bands, which appeared to represent differentially expressed
genes on the basis of their relative intensities on the gels, were
purified for cloning into a pCR2.1 (Invitrogen) vector and se-
quencing.
 
cDNA Cloning and Expression Vectors. 
 
RAW264.7 cDNA li-
brary was constructed in pCR3.1 (Invitrogen) with 5 µg
poly(A)
 
 
 
 RNA from RAW264.7 cells that were treated with 100
ng/ml sRANKL for 48 h using the ZAP Express cDNA synthesis
kit (Stratagene). Based on the sequences of the two mouse EST
clones (AI847606 and AI450325), an oligonucleotide (5
 
 
 
-TC-
CACCCACCAGTTAAGGCCATT-3
 
 
 
 [sense]) was synthesized,
biotinylated, and used for the enrichment of corresponding
cDNA clones from the library by using the GeneTrapper™
cDNA positive selection system (Life Technologies) according to
the manufacturer’s instructions. Similarly, a human homologue of
mouse JDP2 cDNA was isolated from the human spleen cDNA
library (Life Technologies), using an oligonucleotide (5
 
 
 
-
CAGCTCGGCCCTGACTGTGGAG-3
 
 
 
 [sense]) based on a
reported human genomic sequence (GenBank/EMBL/DDBJ ac-
cession no. AF111167). cDNA fragments of JDP2 and RANK
were obtained by PCR amplification and cloned into plasmid
pCR3.1. Each construct was confirmed by DNA sequencing and
Western blot analysis.
 
Northern Blot Analysis. 
 
Total RNA of 15 µg was loaded and
separated on 1% agarose gel containing 6% formaldehyde and
transferred onto Hybond-N
 
 
 
 (Amersham Biosciences) nylon
membranes. The 75-bp fragment of the 3
 
 
 
-terminal in the mouse
JDP2 cDNA or PCR fragments of mouse tartrate-resistant acid
phosphatase (TRAP), cathepsin K, and 
 
 
 
-actin cDNAs were 
 
32
 
P-
labeled using a Random Primer DNA Labeling kit (Takara Bio
Inc.), and the membrane was hybridized with these probes in Ex-
pressHyb buffer (CLONTECH Laboratories, Inc.) according to
the manufacturer’s instructions. The expression levels of each
mRNA were determined using a bioimage analyzer (Fujix
BAS2000; Fuji Co., Ltd.).
 
Quantitative Real-time RT-PCR Analysis. 
 
The mRNA ex-
pression levels of TRAP, cathepsin K, JDP2, and ribosomal 18S
RNA as an endogenous reference, were quantified by a real-time
PCR method (TaqMan Chemistry) on a sequence detection sys-
tem (ABI Prism 7900HT; Applied Biosystems). The quantitative
real-time RT-PCR was performed in a total reaction volume of
50 µl containing 1
 
 
 
 Master Mix without UNG, 1
 
 
 
 Multi-
Scribe™, RNase inhibitor mix (Applied Biosystems), 200 nM for-
ward and reverse primers, 140–200 nM TaqMan Probe, and 100
ng total RNA. Specific primers and probes used for amplification
were as follows: TRAP forward, 5
 
 
 
-CGACCATTGTTAGC-
CACATACG-3
 
 
 
; TRAP reverse, 5
 
 
 
-CACATAGCCCACAC-
CGTTCTC-3
 
 
 
; TRAP probe, 5
 
 
 
-CATGACCACAACCTG-
CAGTATCTTCAGGAC-3
 
 
 
; cathepsin K forward, 5
 
 
 
-
GGGAACGAGAAAGCCCTGA-3
 
 
 
; cathepsin K reverse, 5
 
 
 
-
GTAAAACTGGAAAGATGCCAAGC-3
 
 
 
; cathepsin K probe,
5
 
 
 
-CCATCTCTGTGTCCATCGACGCAAG-3
 
 
 
; JDP2 for-
ward, 5
 
 
 
-CGCTGACATCCGCAACATT-3
 
 
 
; JDP2 reverse, 5
 
 
 
-
GGCCTCTTGCCCAGTTTCA-3
 
 
 
; and JDP2 probe, 5
 
 
 
-
TGCGCCCTTGCACTTCCTGGAG-3
 
 
 
. For detection of ri-
bosomal 18S RNA, the primers and probe were purchased from
Applied Biosystems. Samples were heated at 48
 
 
 
C for 30 min,
95
 
 
 
C for 10 min, and amplified for 40 cycles of 15 s at 95
 
 
 
C and
1 min at 60
 
 
 
C.
 
Antibodies and Western Blot Analysis. 
 
A polyclonal antibody
against mouse JDP2 was generated in rabbits using a syntheticT
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peptide with a sequence, CVKLGKRPQPVKSELD (Cys plus
amino acids 55–69 of mouse JDP2), identical to that of the cor-
responding human peptide. Anti-PU.1 and horseradish peroxi-
dase–linked anti–rabbit IgG were obtained from Santa Cruz Bio-
technology, Inc. and Amersham Biosciences, respectively. To
prepare whole cell extracts, the cells were washed with PBS,
lysed in RIPA buffer (1% NP-40, 0.5% deoxycholic acid, and
0.1% SDS in PBS) supplemented with complete protease inhibi-
tor cocktail (Roche Diagnostics K. K.), and centrifuged. Nuclear
extracts were prepared by essentially the same method as de-
scribed by Schreiber et al. (17), except for the absence of dithio-
threitol in buffers used for cell lysis and extraction of nuclear
proteins. Equal amounts of protein (10–15 µg) were separated in
10–20% gradient SDS-PAGE and electrotransferred onto a poly-
vinylidene difluoride membrane (Bio-Rad Laboratories). Detec-
tion was performed using an ECL Plus Western blotting detection
system (Amersham Biosciences) according to the manufacturer’s
instructions.
 
Preparation of Retrovirus Stocks and Infection of Mouse Primary
Bone Marrow Cells. 
 
A cDNA of mouse JDP2 was inserted into
pMX-puro (18) and pMX–internal ribosome entry site (IRES)–
enhanced green fluorescent protein (EGFP; 19) vectors to con-
struct retrovirus vectors carrying a cDNA for JDP2. The resulting
plasmid (2 µg) was transfected into packaging cell line Bosc 23
(2 
 
 
 
 10
 
6
 
 cells) using FuGENE6 (Roche). After 48 h, the culture
supernatants were collected and used as viral stocks. Bone mar-
row cells (10
 
6
 
) obtained from both femora and tibiae of 6-wk-old
ddY mice were cultured in 
 
 
 
-MEM containing 10% FCS and 10
ng/ml M-CSF overnight in 24-well plates. The medium was re-
placed with the viral supernatant containing 4 µg/ml polybrene,
and the cells were incubated for 4 h at 37
 
 
 
C. Infected cells were
cultured for 2 d in the presence of M-CSF (10 ng/ml), and for
additional 4 d in the presence of both M-CSF (10 ng/ml) and
sRANKL (0, 10, or 30 ng/ml). Adherent cells were fixed with
10% formaldehyde, treated with ethanol–acetone (50:50), and
stained for TRAP activity.
 
Luciferase Constructs, DNA Transfection, and Luciferase Assay.
 
A 1.9-kbp fragment containing the 5
 
 
 
-flanking sequence of
mouse TRAP gene that spans nucleotides –1846 to 
 
 
 
2 from the
ATG codon (20), which was obtained by PCR amplification us-
ing RAW264.7 cell genomic DNA as a template. The 5
 
 
 
-flank-
ing sequence of the mouse cathepsin K gene that spans nucle-
otides –1670 to 
 
 
 
5 from the start of the first exon (21) was also
amplified by PCR. These PCR products were subcloned into the
pGL3-Basic vector (Promega) to place the TRAP or cathepsin K
promoter region upstream of the firefly luciferase gene and gen-
erate pGL3-TRAP or pGL3-CTSK, respectively. The fidelity of
the constructs was verified by nucleotide sequencing. When each
construct was permanently transfected into RAW264.7 cells, the
luciferase activities in both cell lines were significantly increased
by exposure to sRANKL for 24–72 h, although weak or little en-
hancement in the activity was observed in cells stimulated by LPS
or PMA, respectively (unpublished data).
RAW264.7 cells (3–3.5 
 
 
 
 10
 
6
 
) were cotransfected by the
DEAE-dextran (0.5 mg/ml) method with indicated expression
plasmids (3 µg) and a firefly luciferase reporter plasmid (1 µg), to-
gether with a 
 
Renilla
 
 luciferase reporter plasmid pRL-SV40 (0.02
µg; Promega), for the normalization of transfection efficiency.
The next day, cells were incubated with indicated stimuli for in-
dicated periods, and cell extracts were prepared using Passive Ly-
sis Buffer (Promega). Firefly and 
 
Renilla
 
 luciferase activities in the
cell lysates were determined using a Dual-Luciferase
 
®
 
 Assay Sys-
tem (Promega) according to the supplier’s instruction.
 
Results and Discussion
 
Molecular Indexing and Cloning of JDP2. 
 
Exposure to
sRANKL causes the mouse macrophage RAW264.7 cells
to differentiate into osteoclast-like TRAP-positive cells
(6). In an attempt to isolate genes that are induced in
RAW264.7 cells by sRANKL stimulation, and are re-
sponsible for osteoclast differentiation, we used a molecu-
lar indexing technique (16). With this technique, we ob-
tained 10 cDNA clones whose expressions were induced
in RAW264.7 cells by sRANKL stimulation for 48 h
(Fig. 1 A and not depicted). One of them revealed 100%
identity to two mouse EST clones (AI847606 and
AI450325) by BLASTN analysis of the sequence, and is
further characterized in this paper. The full-length cDNA
of this gene, which was obtained from a cDNA library of
RAW264.7 cells, has an open reading frame encoding 163
amino acids whose sequence is identical to that of the rat
cDNA clone, JDP2 (GenBank/EMBL/DDBJ accession
no. U53449, version GI:2833639), indicating that this
gene is a mouse homologue of JDP2. Mouse JDP2 cDNA
has also been cloned by yeast two-hybrid screening, using
activating transcription factor-2 (ATF-2) as the bait (22).
Structurally, JDP2 proteins have three parts: (a) an NH
 
2
 
-
terminal part; (b) a central part that corresponds to a basic
region-leucine zipper domain required for DNA binding
and heterodimerization; and (c) a COOH-terminal part.
Previous papers reported JDP2 as a member of the AP-1
group that can heterodimerize with c-Jun, other Jun pro-
Figure 1. Expression of JDP2 and osteoclast-specific genes at mRNA
and protein levels in RAW264.7 and mouse bone marrow cells. (A)
Northern blot analysis of total RNA (15 µg/lane) prepared from
RAW264.7 cells stimulated with 100 ng/ml sRANKL for indicated peri-
ods. The blots were probed with mouse jdp2 (top), TRAP (center), or
cathepsin K (bottom) cDNA. The same membranes were rehybridized
with  -actin probe. (B) Western blot analysis of RAW264.7 cells stimu-
lated with 100 ng/ml sRANKL for indicated periods. Whole cell extracts
were prepared and subjected (15 µg/lane) using specific antibodies for
JDP2 (top) or PU.1 (bottom). (C) Total RNA was extracted from mouse
bone marrow primary cultures treated with either 25 ng/ml M-CSF
alone or in combination with 100 ng/ml sRANKL for indicated periods.
Expression of mRNA for JDP2, TRAP, or cathepsin K was analyzed by
real-time RT-PCR using ribosomal 18S RNA as an endogenous control.T
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teins (23), and activating transcription factor-2 (ATF-2;
reference 22).
 
Expression of JDP2 in RAW264.7 and Mouse Bone Marrow
Cells. 
 
To elucidate the role of JDP2 in sRANKL-induced
osteoclast differentiation, we analyzed the time course of ac-
cumulation of mRNA for JDP2 and some osteoclast-specific
genes such as TRAP, cathepsin K, and calcitonin receptor.
Expression of mRNA for JDP2 was induced within 5 h after
sRANKL stimulation, reached the peak level at 24 h, and
declined thereafter (Fig. 1 A). In contrast, the mRNA levels
of TRAP, cathepsin K, and calcitonin receptor (unpublished
data) were increased at 24–48 h after the stimulation, and re-
mained elevated until 96 h (Fig. 1 A). The results indicate
that the up-regulation of JDP2 mRNA by sRANK proceeds
induction of expression of osteoclast-specific marker genes
during osteoclast differentiation. On the other hand, LPS
only weakly stimulated JDP2 gene expression and failed to
induce expression of TRAP and cathepsin K genes (unpub-
lished data). Western blot analysis using polyclonal antibody
raised against the peptide sequence of JDP2 also showed that
the level of JDP2 protein was transiently increased by
sRANKL (Fig. 1 B). Importantly, up-regulation of JDP2
mRNA was not detected in mouse macrophage cell line
J774A.1 cells, which lack osteoclastogenic potential in spite
of the fact that they have the same ability to activate the NF-
 
 
 
B pathway as did RAW264.7 (unpublished data). These
results suggest an association between sRANKL-induced
up-regulation of JDP2 and the osteoclast differentiation.
To test this further, we assessed JDP2 gene expression in
mouse bone marrow cells during the differentiation into
TRAP-positive mono- and multinucleated cells. Real-time
quantitative RT-PCR analysis revealed that treatment with
sRANKL in the presence of M-CSF induced an increase in
the levels of mRNA for TRAP and cathepsin K (Fig. 1 C).
In parallel with the induction of these osteoclast-specific
genes, the expression of JDP2 mRNA was found to be up-
regulated by the addition of sRANKL (Fig. 1 C).
 
Infection with JDP2-expressing Retrovirus Promotes Osteoclast
Differentiation In Vitro. 
 
To examine the functional role of
JDP2 in regulating osteoclast differentiation, mouse bone
marrow primary cells were infected with recombinant retro-
virus carrying JDP2 cDNA in vitro. Under our experimen-
tal conditions, we could not detect any TRAP-positive both
mononuclear and multinuclear osteoclasts in the absence of
sRANKL, even after the virus infection (Fig. 2 A). How-
ever, in the presence of a low dose of sRANKL (10 ng/ml)
that failed to induce differentiation to the TRAP-positive
cells, infection with JDP2 retrovirus clearly enhanced the
formation of TRAP-positive mono- and multinuclear cells
(Fig. 2 A). This enhancement was also observed in the pres-
ence of 30 ng/ml sRANKL (Fig. 2 A). Quantitative analysis
showed that the number of the TRAP-positive multi-
nuclear osteoclasts was synergistically increased by infection
Figure 2. Infection with JDP2-expressing retrovirus promotes osteo-
clast generation of mouse bone marrow cells in vitro. Bone marrow cells
prepared from 6-wk-old ddY mice were infected with retrovirus vector
carrying no insert or JDP2 cDNA. The infected cells were treated with
the indicated concentration of sRANKL and stained for TRAP activity
(A). TRAP-positive multinucleated cells containing more than three nu-
clei were counted as osteoclasts (B). (C) Bone marrow cells were infected
with IRES–EGFP retrovirus vector carrying JDP2 cDNA and stimulated
with 10 ng/ml sRANKL. The infected cells were detected by EGFP
fluorescence (left) and stained for TRAP activity (center). The corre-
sponding phase-contrast image is also shown (right). The boundaries of
EGFP-positive multinucleated cells are marked by dotted lines.
Figure 3. Suppression of osteoclast formation by antisense oligonucle-
otide to JDP2 in RAW264.7 cells. (A) RAW264.7 cells (106 cells/well)
cultured in DMEM containing 10% FCS in 60-mm-diameter dishes were
treated with 10 µg/ml S-oligonucleotides (antisense, 5 -ATCATAG-
CAGGAGGAG-3 ; sense, 5 -CTCCTCCTGCTATGAT-3 ) in the
presence of 100 ng/ml sRANKL for 24 h. Nuclear extracts were pre-
pared and subjected to Western blot analysis using antibody for JDP2. (B)
RAW264.7 cells (104 cells/well) cultured in DMEM containing 5% FCS
in 96-well plates were treated with the sense or antisense S-oligonucle-
otide at 100 µg/ml in the presence of 30 ng/ml sRANKL for 4 d. The
cells were fixed and stained for TRAP activity. (C) RAW264.7 cells were
treated with indicated concentrations of the sense or antisense S-oligonu-
cleotide in the presence of sRANKL (30 ng/ml) for 4 d, fixed, and
stained for TRAP activity. TRAP-positive multinucleated cells contain-
ing more than three nuclei were counted as osteoclasts.T
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with JDP2 retrovirus in combination with 10–30 ng/ml
sRANKL (Fig. 2 B), suggesting enhancement of osteoclast
differentiation by JDP2. To detect the cells infected with the
retrovirus encoding JDP2, we used a bicistronic expression
system using the IRES and the EGFP as a selection marker
gene, both of which were placed downstream of JDP2
cDNA. We found that cells expressing EGFP were prefer-
entially differentiated into TRAP-positive multinuclear cells
(Fig. 2 C). These results suggest that JDP2 may act as an in-
termediary to transduce sRANKL-induced osteoclast for-
mation of mouse bone marrow primary cells.
Suppression of Osteoclast Differentiation by Antisense Oligo-
nucleotide to JDP2.  To investigate the essential role of
JDP2 in sRANKL-induced osteoclastogenesis, we at-
tempted to interrupt this process by using antisense oligo-
nucleotide targeted at JDP2. As shown in Fig. 3 A, the
induction of JDP2 protein by sRANKL was largely
suppressed in RAW264.7 cells exposed to JDP2 antisense
oligonucleotide. Treatment with the JDP2 antisense oligo-
nucleotide resulted in a strong inhibition of sRANKL-
induced formation of TRAP-positive mono- and multinu-
clear cells (Fig. 3 B). Quantitative analysis showed that
sRANKL-induced increase in the number of the TRAP-
positive multinuclear osteoclasts was significantly suppressed
by the JDP2 antisense oligonucleotide in a dose-dependent
manner, but not suppressed by the sense oligonucleotide
(Fig. 3 C). These results indicate that JDP2 acts as an essen-
tial factor to induce osteoclast differentiation by sRANKL.
JDP2 Activates the Osteoclastogenic Pathway in RAW264.7
Cells.  To examine the functional role of JDP2 in facili-
tating osteoclast differentiation at the molecular level, we
developed reporter assay systems to detect osteoclastogenic
activity of the protein. RAW264.7 cells were transiently
cotransfected with the expression vector of mouse JDP2
along with the TRAP or cathepsin K promoter–luciferase
construct and the luciferase activity was measured. As
shown in Fig. 4 A, mouse JDP2 enhanced TRAP or
Figure 4. Overexpression of JDP2 stimulates TRAP and cathepsin K
gene promoters in RAW264.7 cells. (A) RAW264.7 cells were cotrans-
fected with indicated expression vector for JDP2 or RANK, together
with the firefly luciferase reporter construct (pGL3-TRAP or pGL3-
CTSK) and pRL-SV40. Cells were either untreated or treated for 24 h
with 100 ng/ml sRANKL before being collected. Relative luciferase ac-
tivity was determined, and the level of induction is indicated as a ratio
with respect to cells transfected with the empty vector in the absence of
sRANKL. Values shown are means   SD of a representative of at least
two independent experiments performed in triplicate. (B) RAW264.7
cells were cotransfected with the indicated dose of expression vectors for
JDP2 with a COOH-terminal HA epitope (JDP2-HA), together with the
firefly luciferase reporter construct (pGL3-TRAP or pGL3-CTSK) and
pRL-SV40. The total amount of DNA in each transfection was kept con-
stant by adding empty vector (pCR3.1) DNA. Cells were either untreated
or treated for 24 h with 100 ng/ml sRANKL before being collected. Rel-
ative luciferase activity was determined as described in A. Values shown
are means   SD of a representative experiment performed in triplicate.
Figure 5. Suppression of sRANKL-induced JDP2 expression and os-
teoclast formation by SP600125 and SB203580 in RAW264.7 cells. (A)
RAW264.7 cells (5   105 cells/well) cultured in DMEM containing 10%
FCS in 6-well plates were pretreated with indicated concentrations of ei-
ther SP600125 or SB203580 for 30 min and stimulated with 100 ng/ml
sRANKL for 24 h. Expression of mRNA for jdp2 was analyzed by real-
time RT-PCR using ribosomal 18S RNA as an endogenous control.
Similar results were obtained from two independent experiments. (B)
RAW264.7 cells (5   103 cells/well) cultured in DMEM containing 10%
FCS in 96-well plates were pretreated with 10 µM of either SP600125 or
SB203580 for 30 min and stimulated with 100 ng/ml sRANKL for 3 d.
The cells were fixed and stained for TRAP activity.T
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cathepsin K promoter activity in these cells to a level com-
parable in magnitude to that observed with mouse RANK,
which is a receptor of RANKL. These elevated activities
were further enhanced by treatment with sRANKL, indi-
cating that JDP2 facilitated sRANKL-induced activation
of these gene expressions. These increases in luciferase ac-
tivity by JDP2 were dependent on the dose of JDP2 plas-
mid used (Fig. 4 B). Similarly, human JDP2 had the ability
to activate both TRAP and cathepsin K promoters in
RAW264.7 cells (unpublished data). Removal of the
NH2-terminal region including the basic region and two
leucine zippers of JDP2 protein completely abolished the
activity to stimulate TRAP and cathepsin K promoters
(unpublished data), suggesting that DNA binding and/or
homo- or heterodimerization are necessary for the activity
of JDP2. These data, along with our findings of suppres-
sion of osteoclast formation by the disruption of expression
of JDP2 by antisense oligonucleotide (Fig. 3), suggest that
JDP2 is a crucial factor to activate the osteoclastogenic
pathway leading to enhancement of TRAP and cathep-
sin K gene expressions, especially in combination with
sRANKL, in RAW264.7 cells.
Requirement of JNK- and p38 Mitogen-activated Protein Ki-
nase (MAPK)–mediated Signals for Inducing JDP2 Expres-
sion  and Osteoclast Differentiation in RAW264.7 Cells.
RANKL has been demonstrated to activate JNK, which
phosphorylates the AP-1 components to potentiate its tran-
scriptional activity, through RANK in osteoclastic cells (6,
13, 24, 25), whereas p38 MAPK-mediated signals have
been shown to regulate osteoclast differentiation (26). To
determine whether the JNK and p38 MAPK pathways
could couple RANK to JDP2 expression, we analyzed
JDP2 mRNA levels of RAW264.7 cells using specific in-
hibitors for JNK and p38 MAPK, SP600125 (27), and
SB203580 (28), respectively. As shown in Fig. 5, both in-
hibitors suppressed sRANKL-induced expression of JDP2
mRNA, as well as formation of TRAP-positive mono- and
multinuclear cells. These results indicate that the JNK and
p38 MAPK pathways play an important role for regulating
JDP2 expression induced by sRANKL. These results fur-
ther support the notion that JDP2 is a crucial factor for
RANKL-mediated osteoclast formation. Although recent
studies showed the ability of JNK and p38 MAPK to phos-
phorylate JDP2 at Thr-148 (29, 30), JDP2 was found in
low abundance in resting cells but its levels were highly in-
duced upon sRANKL stimulation (Fig. 1). Thus, JDP2 ac-
tivity appears to be mainly regulated at the transcriptional
level through JNK and p38 MAPK pathways.
In conclusion, we identified JDP2 as an important sig-
naling molecule for RANK-induced osteoclast differenti-
ation. Further studies on JDP2, including identification of
its partner proteins and generation of JDP2-deficient
mice, will elucidate the precise role of JDP2 in vivo. Such
information on JDP2 will give us not only new insights
into the molecular mechanism regulating bone resorption,
especially osteoclastogenesis, but also give new opportuni-
ties for developing therapeutics to treat diseases of the
bone.
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